Chris H. Miller

California State University, Fresno

2 papers in the library · 2 citations · publishing 2023-2026

Papers

Ketamine pharmacotherapy for major depressive disorder: A narrative review

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 27, 2026 Chris H. Miller, Angela Hickman, Caitlin Baten et al. 2 citations

Ketamine, originally developed as an anesthetic, has emerged as a novel treatment for major depressive disorder (MDD) and treatment-resistant depression (TRD). Its antidepressant properties were discovered serendipitously, leading to FDA approval for TRD and MDD with suicidal ideation. The drug acts primarily as an NMDA receptor antagonist, triggering a paradoxical AMPA-mediated glutamate surge that promotes synaptogenesis and neuroplasticity. Intravenous ketamine and intranasal esketamine differ in dosing, bioavailability, and onset. Common adverse effects include dissociation, sedation, and hypertension. Efficacy studies show mixed-to-positive results, with non-inferiority to established treatments like electroconvulsive therapy. Future research aims to develop predictive markers for personalized medicine.

DOI: 10.1016/j.pnpbp.2026.111651 Major depressive disorder Ketamine Antidepressant Pharmacotherapy +11

The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging Studies

European Psychiatry March 1, 2023 J. H. Shepherd, C.t.m. Baten, A. C. Klassen et al.

Serotonergic psychedelics such as LSD, psilocybin, and MDMA significantly alter neural activation in several regions of the cerebral cortex and basal ganglia. Some effects are common across these drugs, while others are unique to each substance. This meta-analysis combined functional MRI studies of both clinical and healthy participants, using multilevel kernel density analysis with ensemble thresholding. The findings clarify the functional neuroanatomy associated with these drugs and may guide future research into their therapeutic and adverse effects, particularly for emerging psychiatric treatments.

DOI: 10.1192/j.eurpsy.2023.1948 Full text Psilocybin Serotonergic MDMA Psychology +4